2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 72

Autophagy Changes During Aging: A Study In GFP-LC3 Mice
Abstract Number: 1652

Autophagy May Contribute To Glucocorticoid Resistance In Patients With Myositis By Maintaining T Lymphocytes Homeostasis In The Muscles
Abstract Number: 2382

B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab
Abstract Number: 2795

B Cell Derived Cytokines Induce Glomerular Injury in Mice
Abstract Number: 919

B Cell Derived IFN-γ Contributes To The Negative Regulation Of T-Regulatory Cell Differentiation In Arthritis
Abstract Number: 33

B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Abstract Number: 925

B Cell Subset Phenotypes In Patients With Granulomatosis With Polyangiitis (Wegener’s)
Abstract Number: 924

B Cell Subsets and Dysfunction Of Regulatory B Cells In IgG4-Related Diseases and Primary Sjögren Syndrome: The Similarities and Differences
Abstract Number: 1665

B Cells Revisited In Giant Cell Arteritis
Abstract Number: 1870

B-Cell Activating Factor (BAFF) and Pregnancy Outcomes
Abstract Number: 2882

B-Cell Depletion Modulates T-Helper Cell Balance In Patients With Primary Sjögren’s Syndrome
Abstract Number: 912

B-Cell Responses To De Novo Identified Citrullinated Fibrinogen Peptides Are Associated With PTPN22 Risk Allele
Abstract Number: 2797

B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Abstract Number: 917

B-Regulatory-, CD19⁺CD20⁺CD24^highCD38^high -Cells Are Functionally Impaired In Patients With Rheumatoid Arthritis and Healthy First Degree Relatives Compared With Controls
Abstract Number: 2895

Bacterial Amyloids Promote Type I Interferon Production and Accelerate Autoimmunity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].